Beyond hematologic cancers, 22.0405.aF also demonstrated potent activity against ROR1-positive solid tumors, highlighting its translational potential for TNBC, ovarian cancer, and other ROR1-expressing malignancies. Here, ROR1 is linked to hematopoietic and lymphoid cell neoplasm.